{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:23:20Z","timestamp":1772061800845,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010223","name":"Jubileumsklinikens Cancerfond","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010223","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Swedish Society of Medicine"},{"name":"The Gothenburg Society of Medicine"},{"name":"ALF-agreement","award":["ALFGBG-1006089"],"award-info":[{"award-number":["ALFGBG-1006089"]}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Proton radiation therapy (PRT) and mutant isocitrate dehydrogenase inhibitors (mIDH-inhibitors) are emerging therapies for mIDH lower grade gliomas (LGGs). Despite their substantial theoretical benefits, comparisons with current standards \u2013 particularly pertaining to patient-centred outcomes \u2013 are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Through PubMed and Scopus, a search strategy based on keywords focusing on PRT and mIDH-inhibitors was applied on December 3, 2024. Studies in English on at least 20 adult patients (\u2265\u200918\u00a0years) with mIDH-LGG grade 2 or 3 and published between January 1, 2011 and August 31, 2024 were included. Review articles were excluded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 6383 identified articles, seven per treatment strategy were included. Overall survival was not reported for mIDH-inhibitors. The lack of high-quality studies comparing PRT to photon radiation therapy precludes conclusions regarding efficacy, effectiveness or even post-PRT radiological manifestations. For the mIDH-inhibitor Vorasidenib (AG-881), the radiological objective response rate was 10.0\u201342.9%, although lower for contrast-enhancing tumors. Vorasidenib significantly delayed tumor progression (27.7 versus 11.1\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and time to next intervention (not reached versus 17.8\u00a0months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) when compared to placebo. Adverse events were mostly mild, including elevated liver enzymes (15.6\u201344.2%) and headache (26.9\u201346.2%). Only 1\/14 studies included assessments related to quality of life (QoL)-domains with inconclusive research on cognitive outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Studies reporting on patient-centred data including survival, cognition and QoL remain scarce. Larger, comparative prospective studies, preferably randomized controlled trials, with such outcomes are needed to inform clinicians whether the theoretical and radiological benefits can be translated to improved outcomes that matter to patients, i.e. living better and\/or longer.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00701-025-06612-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T04:39:36Z","timestamp":1752899976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A scoping review of proton radiation therapy and mutant-isocitrate dehydrogenase-inhibitors in IDH mutated lower-grade gliomas: pushing beyond surrogate end-points"],"prefix":"10.1007","volume":"167","author":[{"given":"Dima","family":"Harba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Corell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Blomstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asgeir Store","family":"Jakola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"6612_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijrobp.2018.01.099","volume":"101","author":"S Acharya","year":"2018","unstructured":"Acharya S, Robinson CG, Michalski JM, Mullen D, DeWees TA, Campian JL, Chundury A, Bottani B, Hallahan DE, Bradley JD, Huang J (2018) Association of 1p\/19q codeletion and radiation necrosis in adult cranial Gliomas after proton or photon therapy. Int J Radiat Oncol Biol Phys 101:334\u2013343. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.099","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6612_CR2","doi-asserted-by":"publisher","unstructured":"Adeberg S, Harrabi SB, Bougatf N, Verma V, Windisch P, Bernhardt D, Combs SE, Herfarth K, Debus J, Rieken S (2018) Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location. Cancers (Basel) 10:401 https:\/\/doi.org\/10.3390\/cancers10110401","DOI":"10.3390\/cancers10110401"},{"key":"6612_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-019-03297-7","volume":"145","author":"H Ahmad","year":"2019","unstructured":"Ahmad H, Martin D, Patel SH, Donahue J, Lopes B, Purow B, Schiff D, Fadul CE (2019) Oligodendroglioma confers higher risk of radiation necrosis. J Neurooncol 145:309\u2013319. https:\/\/doi.org\/10.1007\/s11060-019-03297-7","journal-title":"J Neurooncol"},{"key":"6612_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/wco.0000000000001316","volume":"37","author":"C Baek","year":"2024","unstructured":"Baek C, Laurenge A, Touat M (2024) Advances in the treatment of IDH-mutant gliomas. Curr Opin Neurol 37:708\u2013716. https:\/\/doi.org\/10.1097\/wco.0000000000001316","journal-title":"Curr Opin Neurol"},{"key":"6612_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.Ccr-23-1180","volume":"30","author":"A Bhatia","year":"2024","unstructured":"Bhatia A, Moreno R, Reiner AS, Nandakumar S, Walch HS, Thomas TM, Nicklin PJ, Choi Y, Skakodub A, Malani R, Prabhakaran V, Tiwari P, Diaz M, Panageas KS, Mellinghoff IK, Bale TA, Young RJ (2024) Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma. Clin Cancer Res 30:106\u2013115. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1180","journal-title":"Clin Cancer Res"},{"key":"6612_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctro.2018.01.002","volume":"9","author":"JK Bronk","year":"2018","unstructured":"Bronk JK, Guha-Thakurta N, Allen PK, Mahajan A, Grosshans DR, McGovern SL (2018) Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. Clin Transl Radiat Oncol 9:30\u201334. https:\/\/doi.org\/10.1016\/j.ctro.2018.01.002","journal-title":"Clin Transl Radiat Oncol"},{"key":"6612_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3171\/2013.1.Jns121","volume":"118","author":"L Capelle","year":"2013","unstructured":"Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H (2013) Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization grade II Gliomas: a series of 1097 cases: clinical article. J Neurosurg 118:1157\u20131168. https:\/\/doi.org\/10.3171\/2013.1.Jns121","journal-title":"J Neurosurg"},{"key":"6612_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"6612_CR9","doi-asserted-by":"publisher","first-page":"vdac124","DOI":"10.1093\/noajnl\/vdac124","volume":"4","author":"NS Cho","year":"2022","unstructured":"Cho NS, Hagiwara A, Eldred BSC, Raymond C, Wang C, Sanvito F, Lai A, Nghiemphu P, Salamon N, Steelman L, Hassan I, Cloughesy TF, Ellingson BM (2022) Early volumetric, perfusion, and diffusion MRI changes after mutant Isocitrate Dehydrogenase (IDH) inhibitor treatment in IDH1-mutant Gliomas. Neurooncol Adv 4:vdac124. https:\/\/doi.org\/10.1093\/noajnl\/vdac124","journal-title":"Neurooncol Adv"},{"key":"6612_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/s1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, D\u00f6hner H (2021) Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 22:1597\u20131608. https:\/\/doi.org\/10.1016\/s1470-2045(21)00494-0","journal-title":"Lancet Oncol"},{"key":"6612_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijrobp.2019.01.003","volume":"104","author":"L Dirven","year":"2019","unstructured":"Dirven L, Reijneveld JC, Taphoorn MJB, Coens C, El-Badawy SA, Tzuk-Shina T, Bravo-Marques J, Back M, Stalpers LJA, Stupp R, Baumert BG, Seidel C (2019) Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033\u201326033. Int J Radiat Oncol Biol Phys 104:90\u2013100. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6612_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.ejca.2015.03.025","volume":"51","author":"L Dirven","year":"2015","unstructured":"Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51:1321\u20131330. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.025","journal-title":"Eur J Cancer"},{"key":"6612_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/s1474-4422(09)70204-2","volume":"8","author":"L Douw","year":"2009","unstructured":"Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810\u2013818. https:\/\/doi.org\/10.1016\/s1474-4422(09)70204-2","journal-title":"Lancet Neurol"},{"key":"6612_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-018-03063-1","volume":"142","author":"M Dworkin","year":"2019","unstructured":"Dworkin M, Mehan W, Niemierko A, Kamran SC, Lamba N, Dietrich J, Martinez-Lage M, Oh KS, Batchelor TT, Wen PY, Loeffler JS, Shih HA (2019) Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol 142:69\u201377. https:\/\/doi.org\/10.1007\/s11060-018-03063-1","journal-title":"J Neurooncol"},{"key":"6612_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-022-04217-y","volume":"162","author":"T Eichkorn","year":"2023","unstructured":"Eichkorn T, Lischalk JW, H\u00f6rner-Rieber J, Deng M, Meixner E, Kr\u00e4mer A, Hoegen P, Sandrini E, Regnery S, Held T, Harrabi S, Jungk C, Herfarth K, Debus J, K\u00f6nig L (2023) Analysis of safety and efficacy of proton radiotherapy for IDH-mutated Glioma WHO grade 2 and 3. J Neurooncol 162:489\u2013501. https:\/\/doi.org\/10.1007\/s11060-022-04217-y","journal-title":"J Neurooncol"},{"key":"6612_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.radonc.2022.08.025","volume":"175","author":"T Eichkorn","year":"2022","unstructured":"Eichkorn T, Lischalk JW, Sandrini E, Meixner E, Regnery S, Held T, Bauer J, Bahn E, Harrabi S, H\u00f6rner-Rieber J, Herfarth K, Debus J, K\u00f6nig L (2022) Iatrogenic influence on prognosis of radiation-induced contrast enhancements in patients with glioma WHO 1\u20133 following photon and proton radiotherapy. Radiother Oncol 175:133\u2013143. https:\/\/doi.org\/10.1016\/j.radonc.2022.08.025","journal-title":"Radiother Oncol"},{"key":"6612_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/0284186x.2023.2200150","volume":"62","author":"H Ek","year":"2023","unstructured":"Ek H, Fagerstr\u00f6m Kristensen I, Stenberg L, Kinhult S, Benedek H, Ek S, Engelholm SA, Engelholm S, Munck Af Rosensch\u00f6ld P (2023) Transitioning from conventional photon therapy to proton therapy for primary brain tumors. Acta Oncol 62:391\u2013399. https:\/\/doi.org\/10.1080\/0284186x.2023.2200150","journal-title":"Acta Oncol"},{"key":"6612_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"6612_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/nop\/npae017","volume":"11","author":"T G\u00f3mez Vecchio","year":"2024","unstructured":"G\u00f3mez Vecchio T, Ryd\u00e9n I, Ozanne A, Blomstrand M, Carstam L, Smits A, Jakola AS (2024) Global health status and fatigue score in isocitrate dehydrogenase-mutant diffuse glioma grades 2 and 3: A longitudinal population-based study from surgery to 12-month follow-up. Neurooncol Pract 11:347\u2013357. https:\/\/doi.org\/10.1093\/nop\/npae017","journal-title":"Neurooncol Pract"},{"key":"6612_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ijrobp.2014.04.053","volume":"89","author":"BA Greenberger","year":"2014","unstructured":"Greenberger BA, Pulsifer MB, Ebb DH, MacDonald SM, Jones RM, Butler WE, Huang MS, Marcus KJ, Oberg JA, Tarbell NJ, Yock TI (2014) Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 89:1060\u20131068. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.04.053","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6612_CR21","unstructured":"Grosshans D, NRG Oncology, National Cancer Institute (NCI) (2017) Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03180502. Accessed 27 Feb 2025"},{"key":"6612_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00066-016-1005-9","volume":"192","author":"SB Harrabi","year":"2016","unstructured":"Harrabi SB, Bougatf N, Mohr A, Haberer T, Herfarth K, Combs SE, Debus J, Adeberg S (2016) Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol 192:759\u2013769. https:\/\/doi.org\/10.1007\/s00066-016-1005-9","journal-title":"Strahlenther Onkol"},{"key":"6612_CR23","doi-asserted-by":"publisher","first-page":"e070071","DOI":"10.1136\/bmjopen-2022-070071","volume":"13","author":"LC Heggeb\u00f8","year":"2023","unstructured":"Heggeb\u00f8 LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset \u00d8, Bergstr\u00f6m P, Agrup M, Dahl L, Gubanski M, Gojon H, Brahme CJ, Ryd\u00e9n I, Jakola AS, Vik-Mo EO, Lie HC, Asphaug L, Hervani M, Kristensen I, Rueegg CS, Olsen IC, Ledal RJ, Degsell E, Werlenius K, Blomstrand M, Brandal P (2023) Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden. BMJ Open 13:e070071. https:\/\/doi.org\/10.1136\/bmjopen-2022-070071","journal-title":"BMJ Open"},{"key":"6612_CR24","doi-asserted-by":"publisher","first-page":"1397912","DOI":"10.3389\/fonc.2025.1397912","volume":"15","author":"LC Heggeb\u00f8","year":"2025","unstructured":"Heggeb\u00f8 LC, Borgen IMH, Blakstad H, Saxhaug C, R\u00f8nning PA, Niehusmann PF, Werlenius K, Blomstrand M, Brandal P (2025) Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3. Front Oncol 15:1397912. https:\/\/doi.org\/10.3389\/fonc.2025.1397912","journal-title":"Front Oncol"},{"key":"6612_CR25","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/jco.21.02929","volume":"41","author":"SL Hervey-Jumper","year":"2023","unstructured":"Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, Lafontaine M, Luks T, Ammanuel S, Kakaizada S, Egladyous A, Gogos A, Villanueva-Meyer J, Shai A, Warrier G, Rice T, Crane J, Wrensch M, Wiencke JK, Daras M, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Jakola AS, Kavouridis VK, Nawabi N, Solheim O, Smith T, Berger MS, Molinaro AM (2023) Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade Glioma. J Clin Oncol 41:2029\u20132042. https:\/\/doi.org\/10.1200\/jco.21.02929","journal-title":"J Clin Oncol"},{"key":"6612_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3171\/2012.8.Jns12393","volume":"117","author":"T Ius","year":"2012","unstructured":"Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, Skrap M (2012) Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. J Neurosurg 117:1039\u20131052. https:\/\/doi.org\/10.3171\/2012.8.Jns12393","journal-title":"J Neurosurg"},{"key":"6612_CR27","doi-asserted-by":"publisher","first-page":"110936","DOI":"10.1016\/j.radonc.2025.110936","volume":"208","author":"L Lauwens","year":"2025","unstructured":"Lauwens L, Ribeiro MF, Zegers CML, H\u00f8yer M, Alapetite C, Blomstrand M, Calugaru V, Perri DD, Iannalfi A, L\u00fctgendorf-Caucig C, Paulsen F, Postma AA, Romero AM, Timmermann B, Troost EGC, van der Weide HL, Whitfield GA, Harrabi S, Lambrecht M, Eekers DBP (2025) Systematic review of MRI alterations in the brain following proton and photon radiation therapy: Towards a uniform European Particle Therapy Network (EPTN) definition. Radiother Oncol 208:110936. https:\/\/doi.org\/10.1016\/j.radonc.2025.110936","journal-title":"Radiother Oncol"},{"key":"6612_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"6612_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.radonc.2019.07.013","volume":"142","author":"VM Lu","year":"2020","unstructured":"Lu VM, Welby JP, Laack NN, Mahajan A, Daniels DJ (2020) Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis. Radiother Oncol 142:36\u201342. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.013","journal-title":"Radiother Oncol"},{"key":"6612_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","volume":"29","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF (2023) Vorasidenib and ivosidenib in IDH1-mutant low-grade Glioma: a randomized, perioperative phase 1 trial. Nat Med 29:615\u2013622. https:\/\/doi.org\/10.1038\/s41591-022-02141-2","journal-title":"Nat Med"},{"key":"6612_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade Glioma. N Engl J Med 389:589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194","journal-title":"N Engl J Med"},{"key":"6612_CR32","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.Ccr-21-0611","volume":"27","author":"IK Mellinghoff","year":"2021","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY (2021) Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive Glioma; results of a first-in-human phase I trial. Clin Cancer Res 27:4491\u20134499. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0611","journal-title":"Clin Cancer Res"},{"key":"6612_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/pbc.21530","volume":"51","author":"TE Merchant","year":"2008","unstructured":"Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U (2008) Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 51:110\u2013117. https:\/\/doi.org\/10.1002\/pbc.21530","journal-title":"Pediatr Blood Cancer"},{"key":"6612_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/neuonc\/5.2.89","volume":"5","author":"CA Meyers","year":"2003","unstructured":"Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5:89\u201395. https:\/\/doi.org\/10.1093\/neuonc\/5.2.89","journal-title":"Neuro Oncol"},{"key":"6612_CR35","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s13311-022-01238-3","volume":"19","author":"JJ Miller","year":"2022","unstructured":"Miller JJ (2022) Targeting IDH-mutant Glioma. Neurotherapeutics 19:1724\u20131732. https:\/\/doi.org\/10.1007\/s13311-022-01238-3","journal-title":"Neurotherapeutics"},{"key":"6612_CR36","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/neuonc\/noac062","volume":"24","author":"CP Millward","year":"2022","unstructured":"Millward CP, Armstrong TS, Barrington H, Brodbelt AR, Bulbeck H, Byrne A, Dirven L, Gamble C, Grundy PL, Islim AI, Javadpour M, Keshwara SM, Krishna ST, Mallucci CL, Marson AG, McDermott MW, Meling TR, Oliver K, Pizer B, Plaha P, Preusser M, Santarius T, Srikandarajah N, Taphoorn MJB, Watts C, Weller M, Williamson PR, Zadeh G, Zamanipoor Najafabadi AH, Jenkinson MD (2022) Opportunities and challenges for the development of \u201ccore outcome sets\u201d in neuro-oncology. Neuro Oncol 24:1048\u20131055. https:\/\/doi.org\/10.1093\/neuonc\/noac062","journal-title":"Neuro Oncol"},{"key":"6612_CR37","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, D\u00f6hner H (2022) Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med 386:1519\u20131531. https:\/\/doi.org\/10.1056\/NEJMoa2117344","journal-title":"N Engl J Med"},{"key":"6612_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00381-019-04420-9","volume":"36","author":"A Muroi","year":"2020","unstructured":"Muroi A, Mizumoto M, Ishikawa E, Ihara S, Fukushima H, Tsurubuchi T, Sakurai H, Matsumura A (2020) Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma. Childs Nerv Syst 36:507\u2013512. https:\/\/doi.org\/10.1007\/s00381-019-04420-9","journal-title":"Childs Nerv Syst"},{"key":"6612_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/neuonc\/noac155","volume":"25","author":"A Natsume","year":"2023","unstructured":"Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K, Mineharu Y, Miyakita Y, Yamasaki F, Matsushita Y, Ichimura K, Ito K, Tachibana M, Kakurai Y, Okamoto N, Asahi T, Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura H, Nishikawa R (2023) The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant Gliomas. Neuro Oncol 25:326\u2013336. https:\/\/doi.org\/10.1093\/neuonc\/noac155","journal-title":"Neuro Oncol"},{"key":"6612_CR40","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jacr.2015.09.019","volume":"12","author":"H Paganetti","year":"2015","unstructured":"Paganetti H, Zietman A (2015) Why Is Proton Beam Therapy So Controversial? J Am Coll Radiol 12:1318\u20131319. https:\/\/doi.org\/10.1016\/j.jacr.2015.09.019","journal-title":"J Am Coll Radiol"},{"key":"6612_CR41","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6612_CR42","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807\u20131812. https:\/\/doi.org\/10.1126\/science.1164382","journal-title":"Science"},{"key":"6612_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/nop\/npad068","volume":"11","author":"KB Peters","year":"2024","unstructured":"Peters KB, Alford C, Heltemes A, Savelli A, Landi DB, Broadwater G, Desjardins A, Johnson MO, Low JT, Khasraw M, Ashley DM, Friedman HS, Patel MP (2024) Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant Glioma. Neurooncol Pract 11:199\u2013204. https:\/\/doi.org\/10.1093\/nop\/npad068","journal-title":"Neurooncol Pract"},{"key":"6612_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01007-z","author":"V Prasad","year":"2025","unstructured":"Prasad V (2025) Surrogate end points in oncology: the speed-uncertainty trade-off from the patients\u2019 perspective. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-025-01007-z","journal-title":"Nat Rev Clin Oncol"},{"key":"6612_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijrobp.2015.06.012","volume":"93","author":"MB Pulsifer","year":"2015","unstructured":"Pulsifer MB, Sethi RV, Kuhlthau KA, MacDonald SM, Tarbell NJ, Yock TI (2015) Early Cognitive Outcomes Following Proton Radiation in Pediatric Patients With Brain and Central Nervous System Tumors. Int J Radiat Oncol Biol Phys 93:400\u2013407. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.06.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6612_CR46","unstructured":"Preusser M, Geurts M, Canadian Cancer Trials Group, Cooperative Trials Group for Neuro-Oncology (COGNO) (2025) Vorasidenib maintenance for IDH mutant astrocytoma (VIGOR). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06809322. Accessed 30-03-2025"},{"key":"6612_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11060-022-04202-5","volume":"162","author":"X Qiu","year":"2023","unstructured":"Qiu X, Gao J, Hu J, Yang J, Hu W, Huang Q, Zhang H, Lu JJ, Kong L (2023) Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center. J Neurooncol 162:503\u2013514. https:\/\/doi.org\/10.1007\/s11060-022-04202-5","journal-title":"J Neurooncol"},{"key":"6612_CR48","doi-asserted-by":"publisher","first-page":"vdad096","DOI":"10.1093\/noajnl\/vdad096","volume":"5","author":"A Retzer","year":"2023","unstructured":"Retzer A, Baddeley E, Sivell S, Scott H, Nelson A, Bulbeck H, Seddon K, Grant R, Adams R, Watts C, Aiyegbusi OL, Kearns P, Rivera SC, Dirven L, Calvert M, Byrne A (2023) Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study. Neurooncol Adv 5:vdad096. https:\/\/doi.org\/10.1093\/noajnl\/vdad096","journal-title":"Neurooncol Adv"},{"key":"6612_CR49","doi-asserted-by":"publisher","first-page":"e057712","DOI":"10.1136\/bmjopen-2021-057712","volume":"12","author":"A Retzer","year":"2022","unstructured":"Retzer A, Sivell S, Scott H, Nelson A, Bulbeck H, Seddon K, Grant R, Adams R, Watts C, Aiyegbusi OL, Kearns P, Cruz Rivera S, Dirven L, Baddeley E, Calvert M, Byrne A (2022) Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study. BMJ Open 12:e057712. https:\/\/doi.org\/10.1136\/bmjopen-2021-057712","journal-title":"BMJ Open"},{"key":"6612_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11060-021-03734-6","volume":"152","author":"R Ritterbusch","year":"2021","unstructured":"Ritterbusch R, Halasz LM, Graber JJ (2021) Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy. J Neurooncol 152:583\u2013590. https:\/\/doi.org\/10.1007\/s11060-021-03734-6","journal-title":"J Neurooncol"},{"key":"6612_CR51","doi-asserted-by":"publisher","first-page":"e856","DOI":"10.1212\/wnl.0000000000009982","volume":"95","author":"I Ryd\u00e9n","year":"2020","unstructured":"Ryd\u00e9n I, Carstam L, Gulati S, Smits A, Sunnerhagen KS, Hellstr\u00f6m P, Henriksson R, Bartek J Jr, Salvesen \u00d8, Jakola AS (2020) Return to work following diagnosis of low-grade Glioma: a nationwide matched cohort study. Neurology 95:e856\u2013e866. https:\/\/doi.org\/10.1212\/wnl.0000000000009982","journal-title":"Neurology"},{"key":"6612_CR52","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2340\/1651-226x.2024.40845","volume":"63","author":"LM Sagberg","year":"2024","unstructured":"Sagberg LM, Salvesen \u00d8, Jakola AS, Thurin E, De Dios E, Nawabi NLA, Kilgallon JL, Bernstock JD, Kavouridis VK, Smith TR, Solheim O (2024) Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas. Acta Oncol 63:798\u2013804. https:\/\/doi.org\/10.2340\/1651-226x.2024.40845","journal-title":"Acta Oncol"},{"key":"6612_CR53","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3171\/2011.7.Jns101238","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai N, Chang S, Berger MS (2011) Low-grade Gliomas in adults. J Neurosurg 115:948\u2013965. https:\/\/doi.org\/10.3171\/2011.7.Jns101238","journal-title":"J Neurosurg"},{"key":"6612_CR54","unstructured":"Sankyo D (2020) A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04458272. Accessed 27 Feb 2025"},{"key":"6612_CR55","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/cncr.29237","volume":"121","author":"HA Shih","year":"2015","unstructured":"Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, Winrich BK, Batchelor TT, Thornton LT, Mancuso SM, Saums MK, Oh KS, Curry WT, Loeffler JS, Yeap BY (2015) Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer 121:1712\u20131719. https:\/\/doi.org\/10.1002\/cncr.29237","journal-title":"Cancer"},{"key":"6612_CR56","doi-asserted-by":"publisher","first-page":"e097810","DOI":"10.1136\/bmjopen-2024-097810","volume":"15","author":"F Slevin","year":"2025","unstructured":"Slevin F, Hudson EM, Boele FW, Powell JR, Noutch S, Borland M, Brown S, Bruce A, Bulbeck H, Burnet NG, Chang YC, Colaco R, Currie S, Egleston D, Fersht N, Klein M, Lilley J, Lowe M, Miles E, Murray RD, O\u2019Hara DJ, Norris M, Parbutt C, Smith A, Smith C, Whitfield GA, Short S, Murray L (2025) APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health - study protocol paper for a phase III multicentre, open-label randomised controlled trial. BMJ Open 15:e097810. https:\/\/doi.org\/10.1136\/bmjopen-2024-097810","journal-title":"BMJ Open"},{"key":"6612_CR57","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.04.027","volume":"137","author":"S Tabrizi","year":"2019","unstructured":"Tabrizi S, Yeap BY, Sherman JC, Nachtigall LB, Colvin MK, Dworkin M, Fullerton BC, Daartz J, Royce TJ, Oh KS, Batchelor TT, Curry WT, Loeffler JS, Shih HA (2019) Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol 137:95\u2013101. https:\/\/doi.org\/10.1016\/j.radonc.2019.04.027","journal-title":"Radiother Oncol"},{"key":"6612_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/j.seminoncol.2003.11.023","volume":"30","author":"MJ Taphoorn","year":"2003","unstructured":"Taphoorn MJ (2003) Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol 30:45\u201348. https:\/\/doi.org\/10.1053\/j.seminoncol.2003.11.023","journal-title":"Semin Oncol"},{"key":"6612_CR59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jocn.2021.03.038","volume":"88","author":"KX Teng","year":"2021","unstructured":"Teng KX, Price B, Joshi S, Alukaidey L, Shehab A, Mansour K, Toor GS, Angliss R, Drummond K (2021) Life after surgical resection of a low-grade glioma: A prospective cross-sectional study evaluating health-related quality of life. J Clin Neurosci 88:259\u2013267. https:\/\/doi.org\/10.1016\/j.jocn.2021.03.038","journal-title":"J Clin Neurosci"},{"key":"6612_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.clineuro.2018.08.003","volume":"174","author":"E Thurin","year":"2018","unstructured":"Thurin E, Nystr\u00f6m PW, Smits A, Werlenius K, B\u00e4ck A, Liljegren A, Daxberg EL, Jakola AS (2018) Proton therapy for low-grade gliomas in adults: a systematic review. Clin Neurol Neurosurg 174:233\u2013238. https:\/\/doi.org\/10.1016\/j.clineuro.2018.08.003","journal-title":"Clin Neurol Neurosurg"},{"key":"6612_CR61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/edbk_238353","volume":"39","author":"MC Tom","year":"2019","unstructured":"Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS (2019) Management for different Glioma subtypes: are all low-grade Gliomas created equal? Am Soc Clin Oncol Educ Book 39:133\u2013145. https:\/\/doi.org\/10.1200\/edbk_238353","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"6612_CR62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/m18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\u00e7alp \u00d6, Straus SE (2018) PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/m18-0850","journal-title":"Ann Intern Med"},{"key":"6612_CR63","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/s0140-6736(05)67070-5","volume":"366","author":"MJ van den Bent","year":"2005","unstructured":"van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstr\u00f6m PO, Collette L, Pi\u00e9rart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985\u2013990. https:\/\/doi.org\/10.1016\/s0140-6736(05)67070-5","journal-title":"Lancet"},{"key":"6612_CR64","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","volume":"20","author":"A Walia","year":"2023","unstructured":"Walia A, Tuia J, Prasad V (2023) Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nat Rev Clin Oncol 20:885\u2013895. https:\/\/doi.org\/10.1038\/s41571-023-00823-5","journal-title":"Nat Rev Clin Oncol"},{"key":"6612_CR65","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1158\/1078-0432.Ccr-20-4256","volume":"27","author":"A Wick","year":"2021","unstructured":"Wick A, B\u00e4hr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Pe\u00f1a C, Tabatabai G (2021) Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors. Clin Cancer Res 27:2723\u20132733. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4256","journal-title":"Clin Cancer Res"},{"key":"6612_CR66","doi-asserted-by":"publisher","first-page":"e1748","DOI":"10.1093\/oncolo\/oyae195","volume":"29","author":"SF Winter","year":"2024","unstructured":"Winter SF, Gardner MM, Karschnia P, Vaios EJ, Grassberger C, Bussi\u00e8re MR, Nikolic K, Pongpitakmetha T, Ehret F, Kaul D, Boehmerle W, Endres M, Shih HA, Parsons MW, Dietrich J (2024) Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2\u20133 gliomas. Oncologist 29:e1748\u2013e1761. https:\/\/doi.org\/10.1093\/oncolo\/oyae195","journal-title":"Oncologist"},{"key":"6612_CR67","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00520-011-1288-4","volume":"20","author":"C Yavas","year":"2012","unstructured":"Yavas C, Zorlu F, Ozyigit G, Gurkaynak M, Yavas G, Yuce D, Cengiz M, Yildiz F, Akyol F (2012) Prospective assessment of health-related quality of life in patients with low-grade glioma: a single-center experience. Support Care Cancer 20:1859\u20131868. https:\/\/doi.org\/10.1007\/s00520-011-1288-4","journal-title":"Support Care Cancer"},{"key":"6612_CR68","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00066-024-02229-3","volume":"200","author":"H Yu","year":"2024","unstructured":"Yu H, He S, He Y, Dai G, Fu Y, Zeng X, Liu M, Ai P (2024) Dosimetric comparison of advanced radiation techniques for scalp-sparing in low-grade gliomas. Strahlenther Onkol 200:785\u2013796. https:\/\/doi.org\/10.1007\/s00066-024-02229-3","journal-title":"Strahlenther Onkol"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-025-06612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-025-06612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-025-06612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T04:39:41Z","timestamp":1752899981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-025-06612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6612"],"URL":"https:\/\/doi.org\/10.1007\/s00701-025-06612-6","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval from an ethics committee or institutional review board was required as no access to sensitive patient information nor any direct involvement of human\/animal participants was included in this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Author P.B. declares honoraria for lectures, consultation or advisory board participation from Servier, Ekspertpanelet and Moloklinikken.The remaining authors have no conflicts of interest to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}